完全性胸段脊髓损伤患者急性植入生物可吸收聚合物支架:INSPIRE 研究 24 个月随访
INSPIRE 为前瞻性、开放标签、多中心、单臂研究,评估急性植入研究性生物可吸收聚合物装置(Neuro-Spinal Scaffold,NSS)在完全性胸段脊髓损伤患者中的安全性。19 例患者接受植入,16 例可评估患者中 7 例(44%)在 6 个月时 AIS 分级改善至少 1 级至 AIS B(5 例)或 AIS C(2 例),24 个月随访期间无长期神经学问题,部分患者 12 个月及以后出现额外 AIS 转换。
要点
- 19 例完全性胸段脊髓损伤患者急性植入 NSS,3 例早期死亡经研究者判定与 NSS 或其植入操作无关。
- 16 例可评估患者中 7 例(44%)在 6 个月时 AIS 分级改善至少 1 级至 AIS B(5 例)或 AIS C(2 例)。
- 6 个月时为 AIS B 的 3 例患者在 12 个月(2 例)和 24 个月(1 例)进一步改善至 AIS C,至最新随访无患者恶化。
核心结论
- 在这小组完全性胸段脊髓损伤患者中,急性 NSS 植入脊髓内似乎安全,24 个月随访期间未发现长期神经学问题。
- 患者保持稳定,部分患者在 12 个月及以后观察到额外 AIS 转换。
- 这些数据进一步支持 NSS 植入在该患者人群中的安全性和可能获益。
研究设计与样本
- INSPIRE 为前瞻性、开放标签、多中心、单臂研究(NCT02138110)。
- 纳入标准为创伤性非穿透性脊髓损伤、MRI 可见挫伤、AIS A 分级、神经损伤平面 T2-T12、伤后 96 小时内需开放脊柱手术。
- 19 例患者接受 NSS 植入,其中 16 例可评估。
主要发现
- 3 例患者早期死亡,研究者判定与 NSS 或其植入操作无关。
- 16 例可评估患者中 7 例(44%)在 6 个月(主要终点)时 AIS 分级改善至少 1 级至 AIS B(5 例)或 AIS C(2 例)。
- 6 个月时为 AIS B 的 3 例患者中,2 例在 12 个月、1 例在 24 个月进一步改善至 AIS C;至最新可获随访无患者恶化。
- 未报告非预期或严重器械不良事件。
局限性
- 原文结论称该研究为小样本患者组(small group of patients)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Based on 6-month data from the InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold for Safety and Neurological Recovery in Patients with Complete Thoracic Spinal Cord Injury (INSPIRE) study (NCT02138110), acute implantation of an investigational bioresorbable polymer device (Neuro-Spinal Scaffold [NSS]) appeared to be safe in patients with complete thoracic spinal cord injury (SCI) and was associated with an ASIA Impairment Scale (AIS) conversion rate that exceeded historical controls. OBJECTIVE: To evaluate outcomes through 24 months postimplantation. METHODS: INSPIRE was a prospective, open-label, multicenter, single-arm study. Eligible patients had traumatic nonpenetrating SCI with a visible contusion on MRI, AIS A classification, neurological level of injury at T2-T12, and requirement for open spine surgery ≤96 hours postinjury. RESULTS: Nineteen patients underwent NSS implantation. Three patients had early death determined by investigators to be unrelated to the NSS or its implantation procedure. Seven of 16 evaluable patients (44%) had improvement of ≥1 AIS grade at 6 months (primary end point) to AIS B (n = 5) or AIS C (n = 2). Three patients with AIS B at 6 months had further neurological improvement to AIS C by 12 (n = 2) and 24 (n = 1) months, respectively; none have deteriorated per latest available follow-up. No unanticipated or serious adverse device effects were reported. CONCLUSION: In this small group of patients with complete thoracic SCI, acute NSS implantation within the spinal cord appeared to be safe with no long-term neurological issues identified during the 24-month follow-up. Patients remain stable, with additional AIS conversions observed in some patients at 12 months and beyond. These data further support the safety and probable benefit of NSS implantation in this patient population.
引用
- Kim KD, Lee KS, Coric D, et al. Acute Implantation of a Bioresorbable Polymer Scaffold in Patients With Complete Thoracic Spinal Cord Injury: 24-Month Follow-up From the INSPIRE Study. Neurosurgery. 2022. PMID: 35442254. doi:10.1227/neu.0000000000001932
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。